Delivery Order SPE2DB20D2014-SPE2DB25FC49F
- Not listed
- The Defense Logistics Agency awarded a $18,496.02 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 14, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a $12,330.68 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors on September 18, 2025, with an ultimate completion date of October 9, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus, representing a specialty...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on August 28, 2025, with completion anticipated by September 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on September 8, 2025, with completion targeted for September 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and lupus nephritis, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 21, 2025, with completion scheduled for September 12, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody immunosuppressant medication used primarily to treat systemic lupus...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injector on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC49FDelivery Order
The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector on July 17, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody treatment indicated for systemic lupus erythematosus and other autoimmune conditions, representing a specialized pharmaceutical product critical for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a prime vendor for federal medical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 7/17/25 |